<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.46624/ajptr.2020.v10.i5.005</article-id>
      <article-id pub-id-type="publisher-id">AJPTR105005</article-id>
      <title-group>
        <article-title>Bilayer Tablet of Atenolol and Simvastatin</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Datir</surname>
            <given-names>M. B.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chechare</surname>
            <given-names>D.D.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dhambore</surname>
            <given-names>Bhagyashree</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ansari</surname>
            <given-names>Shaheen</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2020-10-01">
        <month>10</month>
        <day>01</day>
        <year>2020</year>
      </pub-date>
      <volume>10</volume>
      <issue>5</issue>
      <abstract>
        <p>Bilayer tablets are planned by way of one layer of drug for immediate release with the second layer designed to release drug later, either as a second dose or in an sustained release form. The bilayer tablets with two incompatible drugs can also be prepared by compressing separate layers of each drug so as to minimize area of contact between two layers of two API. To manufacture sufficient tablet formulation, definite necessities such as sufficient mechanical strength and desired drug release profile must be meet. At times, this may be difficult task for formulator to achieve these conditions especially in bilayer tablet formulation where double compression technique is involved, because of poor flow and compatibility characteristic of the drug which will result in capping and/or lamination. The compaction of a material involves both the compressibility and consolidation.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Bilayer</kwd>
        <kwd>Compression</kwd>
        <kwd>Release</kwd>
        <kwd>tablet</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
